{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:36:06Z","timestamp":1785576966032,"version":"3.56.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dienogest provided significantly greater reduction in endometriosis-associated pelvic pain (EAPP) than placebo in a 24-week, randomized, double-blind study of Chinese women with endometriosis. The current open-label extension study investigated the efficacy and safety of dienogest for 28 additional weeks in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      Women with endometriosis were eligible to enroll at completion of the 24-week, placebo-controlled study (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009220). All women, regardless of prior study treatment, received dienogest 2\u2009mg once daily for up to 28 weeks. Absolute change in EAPP from baseline on a 1\u2013100\u2009mm visual analog scale (VAS), bleeding pattern, adverse events (AEs), laboratory parameters, and bone mineral density (BMD) were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The open-label study was completed by 203 (92.3%) women. At the end of open-label study, mean (SD) change from baseline in EAPP score on VAS was \u221243.1\u2009mm (26.54\u2009mm) and \u221239.8\u2009mm (31.15\u2009mm) in the prior-dienogest and prior-placebo groups, respectively. Other assessments confirmed that dienogest maintained or enhanced efficacy after 28 weeks of additional treatment. Dienogest initiation was associated with longer, but fewer, spotting\/bleeding episodes. Bleeding frequency and intensity decreased progressively during continued treatment. Treatment-emergent AEs, generally mild or moderate, led to withdrawal in 2 (0.9%) patients during the open-label study. Dienogest had no effect on BMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Dienogest 2\u2009mg once daily is effective and safe in the long-term management of EAPP in Chinese women with endometriosis, with progressive decreases in EAPP and bleeding irregularities during continued treatment. Efficacy and safety results of this study were consistent with previous studies in Caucasian patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jwh.2018.7084","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T11:48:03Z","timestamp":1542800883000},"page":"170-177","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["Dienogest for Treatment of Endometriosis in Women: A 28-Week, Open-Label, Extension Study"],"prefix":"10.1177","volume":"28","author":[{"given":"Qi","family":"Yu","sequence":"first","affiliation":[{"name":"Peking Union Medical College Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shengjing Hospital of China Medical University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajun","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University Third Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Huaxi Second Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Zvolanek","sequence":"additional","affiliation":[{"name":"Bayer AG","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Ren","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Co. Ltd.","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Dong","sequence":"additional","affiliation":[{"name":"Bayer AG","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghe","family":"Lang","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/1933719108330087"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.03.069"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)54244-7"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2012.06.029"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmp007"},{"key":"e_1_3_4_7_2","first-page":"CD004753","article-title":"Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis","volume":"1","author":"Brown J","year":"2017","unstructured":"Brown J, , Crawford TJ, , Allen C, , Hopewell S, , Prentice A. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev, 2017; 1:CD004753.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/det457"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2017.01.003"},{"key":"e_1_3_4_10_2","first-page":"CD008475","article-title":"Gonadotrophin-releasing hormone analogues for pain associated with endometriosis","author":"Brown J","year":"2010","unstructured":"Brown J, , Pan A, , Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev, 2010:CD008475.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.08.057"},{"key":"e_1_3_4_12_2","first-page":"CD002122","article-title":"Progestagens and anti-progestagens for pain associated with endometriosis","author":"Brown J","year":"2012","unstructured":"Brown J, , Kives S, , Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev, 2012:CD002122.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-015-0909-7"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2217\/WHE.09.72"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.11.042"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1380216"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.09.040"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew180"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S5633"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.12.080"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2009.08.020"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2010.04.002"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep469"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2012.01.009"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2017.6399"},{"key":"e_1_3_4_26_2","first-page":"161","article-title":"[Guideline for the diagnosis and treatment of endometriosis]","volume":"50","author":"Cooperative Group of Endometriosis, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association","year":"2015","unstructured":"Cooperative Group of Endometriosis, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. [Guideline for the diagnosis and treatment of endometriosis]. Zhonghua Fu Chan Ke Za Zhi, 2015; 50:161\u2013169.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmu046"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-138"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-011-1941-7"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(81)90478-6"},{"key":"e_1_3_4_31_2","unstructured":"Ware JE Kosinski M Dewey JE. How to score version 2 of the SF-36 health survey. Lincoln RI: QualityMetric Inc.; 2005."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2009.01076.x"},{"key":"e_1_3_4_33_2","volume-title":"Presented at: 2nd Congress of the Society of Endometriosis and Uterine Disorders","author":"Yarmolinskaya M","unstructured":"Yarmolinskaya M, , Makarova I, , Veremiova R, et al. A non-interventional study with dienogest 2\u2009mg to assess the quality of life in patients with endometriosis (DIVA study). Presented at: 2nd Congress of the Society of Endometriosis and Uterine Disorders; May 12\u201314, 2016; Barcelona, Spain. Abstract 1576."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1876"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2018.7084","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2018.7084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2018.7084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:48:51Z","timestamp":1777657731000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2018.7084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1089\/jwh.2018.7084"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2018.7084","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}